Who are we?
Neurim Pharmaceuticals Ltd. is a drug discovery and development company, focused on the central nervous system (CNS), primarily in age-related disorders.
Our main goal is to improve the quality of life.
Circadin®, the company’s novel product for insomnia, was approved by the European Commission on the 29th June 2007 and is currently marketed in Europe, Asia-Pacific, Latin America, Africa and the Middle East. Other products are NCEs at preclinical and clinical development.
Neurim Pharmaceuticals was founded in 1991 by Prof. Nava Zisapel, a recognized neuroscientist and by the entrepreneur and businessman Mr. Yehuda Zisapel, who is also founder and director of the RAD Group, a high-tech group specializing in data communication and chairman of Rad-Biomed, a biomedical start-up incubator.
Through academic research on neurobiology, Prof. Zisapel, hypothesized that age-related sleep complaints are linked to the decay in production of melatonin. These findings initiated the creation of Neurim Pharmaceuticals, a company focused on age-related disorders such as insomnia and Alzheimer’s disease, primarily in the central nervous system (CNS).
Drugs Disributed by Neurim Pharmaceuticals Limited
melatonin receptor agonists. Melatonin 2 mg. PR TABS: 2 mg X 21, 30. 1 tab. dly, 1-2 hrs bef. bedt., and aft. food. Cont. for 13 wks.
Not recommend. in child. and adolesc.
below 18 yrs. Hepat. impair: Not
recommend.
Short-term tmt. prim. insomn. in poor
quality sleep in pts. 55 or over.
C/I: Hypersens.
melatonin receptor agonists. Melatonin 1 mg, 5 mg. PR Tabs: 60 X 1 mg, 30 X 5mg. Recommend. Start. dose 2 mg. If inadeq. response observ., dose should be incr. to 5 mg, with a max. dose of 10 mg.
Drug should be taken once dly., 0.5-1 hr. before bedtime, with or after food.
Tmt. of insomnia in child. and adolesc. aged 2-18 with ASD and / or Smith-Magenis syndr., where sleep hygiene meas. have been insuff.
C/I: Hypersens.
